Banking Transformation – The Top 5 Issues & Insights
Acing Strategy: A Key Skill for Game-Changing CIOs
Concerned about the future of bio-pharma? Well, keep these two very important things in mind…
It is a time of uncertainty for leaders in the biotech and pharma industries. However, as this article shows, the industry’s importance and resilience has never been clearer.
The news headlines are a cause for concern: Firings, resignations & chaos at the FDA. The agency that responded to the pandemic with warp speeds could now be moving at a snail’s pace.
With vaccine sceptics as its political overlords, all this adds another layer of uncertainty to an already very high-stakes business model. Up to 50 biotech IPOs forecast for 2025 could be at risk1. No wonder many bio-pharma executives are reaching for the anxiety medicine.
Contrast this to the fortunes of Ai, where one Ai stock market launch can raise as much as 15 biotech launches. The average biotech IPO is approx $200 million2, but one Ai IPO (CoreWeave) in March 2025 raised 1.5 bn.3
- Eli Lilly: $782.95 billion
- Novo Nordisk: $452.8 billion
- Johnson & Johnson: $377.7 billion
- Merck & Co.: $263.9 billion
- AbbVie: $261.2 billion
- Roche: $222.4 billion
However, there is one way in which bio-pharma will always be Number 1: in terms of benefits to humanity. The world needs more & better medicines with up to a third of adults living with a long-standing illness or health problem4.
The challenges facing bio-pharma are extraordinary, and the response to them needs to be extraordinary too. As our research shows, the industry’s leaders are doubling-down on their super projects, staying the course in terms of their ambitious strategies for growth, innovation & transformation.
This period of turbulence in bio-pharma won’t last forever. The industry has faced turbulent times before, only to end up stronger as a result. Moreover, the importance of the industry has never been clearer, especially in the face of Chinese competition.
‘Biotech is foundational to national security & economic power in the 21st century,’ says a new congressional report that calls for major government funding & support5. Like Congress, we believe in the future of the bio-pharma industry. Also, in the creativity, resilience and determination of its leaders.
Join us in celebrating bio-pharma’s super projects and the executives who are going through walls to make them happen.
Get your FREE Copy at www.Super-Projects.co.
Super Projects is an initiative lead by Growth Pitstop.
SOLUTIONS & SERVICES: Here are some of the ways that our research & insights are put to work by our clients:
- See: https://patentpc.com/blog/biotech-ipos-in-2020-2030-how-many-companies-are-going-public-investment-data?utm_source=chatgpt.com [↩]
- See: https://www.jdsupra.com/legalnews/life-sciences-under-the-microscope-key-1328430/#:~:text=significant%20uptick%2C%20with%20%243,Later%20in%20the [↩]
- CoreWeave, an AI-focused cloud infrastructure company backed by Nvidia, completed its IPO in March 2025. See: https://www.investors.com/news/technology/coreweave-stock-ai-stock-crwv-news-ipo-nvidia-openai/?utm_source=chatgpt.com )
The stock market values Ai dreams above scientific-medical breakthroughs, with Ai giant NVIDIA’s valuation being the equivalent of the Top 6 players in pharma. These companies are: ((It takes the top 6 pharmaceutical companies to reach a total valuation of approximately $2.36 trillion (just above NVIDIA’s April 2024 valuation). [↩]
- OECD Research 2021, link: https://www.oecd.org/en/topics/policy-issues/chronic-diseases.html?utm_source=chatgpt.com [↩]
- See NSCEB report 8 April 2025, Link: https://www.biotech.senate.gov/press-releases/nsceb-publishes-final-report/ [↩]
